
Physician-scientist @WashUPain working to understand and address neuropathic pain https://nitter.cf/t.co/mDgTxPK4oT
St Louis, MO
Joined September 2008
- Tweets11.5K
- Following4.8K
- Followers2.7K
- Likes29.7K
Pinned Tweet
Last week I finished pain fellowship, concluding a nearly 20 year journey of training & life. What a ride!
So what is next? I'm thrilled to announce that I will be starting my integrated lab and clinical practice @WashUPain focused on the study and treatment of #neuropathic pain.
Alex Chamessian retweeted
My time at the Gates Foundation/IDM recently wrapped up! I'm looking for senior/staff roles in AI for science, probabilistic inference, or scientific software — in Seattle or the SF Bay Area.
Also open to consulting.
Here's what I've been working on:
Alex Chamessian retweeted
🚀 Rxiv-Maker is now peer-reviewed and open access! Write in Markdown, get a typeset PDF or an editable Word file, with figures, citations and cross-references numbered for you. Led by @Bruno_MSaraiva with Guillaume Jacquemet's lab 🔬
doi.org/10.1242/jcs.265183
Alex Chamessian retweeted
Our clinical trial of AMIE, a patient-facing AI system, was just published in The Lancet.
I want to explain what *I* think this study ACTUALLY means.
It's about a fundamental question: how do we know that clinical AI works?
🧵⬇️
nitter.cf/Google/status/21083245…
Our medical research system, AMIE, is the first patient-facing conversational diagnostic tool of its kind to be studied prospectively in a real-world clinical setting.
In a study, published today in @TheLancet, we found that when patients chatted with AMIE before an in-person appointment, the interaction built their confidence and helped them organize their thoughts. And physicians who reviewed the information from the patient conversation got more time back to focus on collaborative care and shared decision-making instead of digging through data.
Alex Chamessian retweeted
Most research problems I see start before the research: the question isn't sharp yet, and everything downstream is thus murky.
So I built Question First, a free tool that gets your question and logic clear before you start. questionfirst.org 🧵
Alex Chamessian retweeted
Our Department of Pharmacology at the University of Minnesota @UMNews is looking for another tenure-track Assistant Professor! Please pass along to those in your network who may be interested.
Join us! 👉 jobs.sciencecareers.org/job/…
#Hiring #FacultyJobs #TenureTrack
Alex Chamessian retweeted
What if,
for any scientific claim,
you can search 100M+ papers to find the strongest evidence for and against it
⚡️in 1 second?
That’s now possible with Evidence API! 🚀
paperclip.gxl.ai/evidence-ap…
For example, does drinking coffee reduce diabetes risk?
Alex Chamessian retweeted
How did a $1 billion drug come out of my lab?
I was a basic scientist with zero background in clinical trials, a fledgling assistant professor at @washumedicine. My secret: I asked stupid questions and ignored the conventional wisdom.
Around 2014, we realized JAK1 is expressed in sensory neurons. When we deleted JAK1 in itch nerves, the mice stopped scratching. We predicted JAK1 inhibition would be a major drug target for itch in @CellCellPress. We even got a patent.
@Incyte already had Jakafi (ruxolitinib) approved for myeloproliferative disorders, so I approached them about oral Jakafi for itch. Their answer: "Design a trial, but can you do it with topical ruxolitinib?"
So I designed the pivotal phase 2 trial at a @Starbucks.
What happened next was nothing short of amazing. Incyte had no dermatology division at the time, which meant nobody told me what I couldn't do. I designed the boldest trial imaginable: ruxolitinib head-to-head against triamcinolone 0.1%, the gold standard medium-potency steroid. No dermatology company in its right mind would take that risk.
When the trial read out, I literally celebrated. Topical ruxolitinib showed incredible efficacy across all doses, and it beat triamcinolone on itch. That led to a phase 3 trial and then approval.
Opzelura was approved in 2021, and Incyte's 2026 guidance projects roughly $1.05 to $1.1 billion in net sales. Topical steroids are falling out of favor.
The drug is amazing. Science matters.
Our goal is to do this over and over again @NorthwellHealth.
Alex Chamessian retweeted
Jodi's leg was amputated after a severe bone infection—so why was her missing leg still causing her pain? Thanks to @WashUPain and @achamess, Jodi regained her independence with spinal cord stimulation. Read her story: heyor.ca/AF4Ewx
Alex Chamessian retweeted
Chief Scientific Officer Search at the AOI
The Ackman Oxman Institute (AOI) is a new translational neuroscience, rehabilitation, and brain health institute in New York City founded to accelerate the translation of promising science to treating and curing patients.
We are seeking a Chief Scientific Officer (CSO) who shares our ambition and recognizes that transformative advances depend on creative, independent scientists pursuing fundamental questions relevant to brain injury, degeneration, recovery, and rehabilitation.
The CSO will help shape AOI's scientific identity, organization, and culture. We welcome the candidate's ideas about how best to organize the science and create an environment in which outstanding investigators can do their best work.
Mandate
Lead AOI's discovery science enterprise. Working with the Chief Translational Officer (CTO) and institute leadership, the CSO will define the research agenda, recruit and develop exceptional scientists, and determine the mix of investigator-led laboratories, collaborative teams, shared resources, and external partnerships best suited to the mission. The portfolio will support two complementary kinds of work:
Patient-Anchored Translational Programs
Research developed in anticipation of, as well as in response to, clinical observations. For example, a mechanistic program on mitochondrial delivery and bioenergetic rescue could inform a parallel clinical study of mitochondrial transplantation. Programs pursuing a defined path to patients will have clear milestones and criteria for advancement, redirection, or stopping, appropriate to their stage of development.
Mission-Relevant Discovery Science
Protected support for fundamental research on brain injury, repair, plasticity, and aging, led by investigators with intellectual independence. Major continuation or stop decisions will use a five-to-seven-year horizon, with ongoing scientific exchange and peer review to maintain rigor. This work can generate new therapeutic ideas and give AOI the depth to recognize and pursue discoveries arising from patient studies.
The CSO will shape the balance between these forms of research and how they interact, with resources and review practices suited to each. Scientists will have the freedom to pursue original ideas within AOI's mission and contribute to a collaborative scientific community.
Scope and Responsibilities
Scientific Portfolio
Define the research agenda with the CTO across acquired brain injury (stroke, TBI), and neurodegenerative and neuropsychiatric diagnoses as well brain health in aging. Build on AOI's initial priorities in bioenergetics/mitochondria, neuroinflammation, and neuroplastogens (devices or biologics that increase neuroplasticity), helping refine their scope, sequence, and organization. Identify promising mechanistic programs early so AOI is prepared to act on clinical discoveries, and welcome new ideas through a transparent scientific review process.
Independent Discovery
Recruit exceptional investigators and give them the resources and latitude to pursue fundamental questions relevant to AOI's mission. Develop peer review that evaluates scientific quality, originality, and contribution over an appropriate time horizon, recognizes the value of well-reasoned negative results, and protects intellectual independence.
Scientific Infrastructure
Determine which laboratory and measurement capabilities will best support the science, and which to build internally, share, or access through partnerships. Guide scientific use of shared resources, including GLP vivarium and GMP capabilities, in coordination with the CTO and Chief Regulatory Officer.
Scientific Recruitment and Community
Shape a recruitment and support model that attracts outstanding scientists with diverse approaches to discovery and collaboration. Explore joint or affiliated academic appointments and shared recruitment with New York City and regional universities and medical centers, where these strengthen recruitment, mentorship, and scientific exchange. Appointment arrangements will be developed with partner institutions and individual recruits.
External Scientific Network
Build a network of well-funded collaborations with academic laboratories in New York City and the region whose fundamental work is relevant to AOI's mission, so that AOI's discovery capacity extends well beyond its own walls. The Pershing Square MIND Prize community is a natural springboard for this network, though collaboration is not limited to prize recipients. Work with the founders on how the MIND Prize and AOI's basic research program should relate to each other over time.
Scientific Quality
Lead a collegial, rigorous scientific review process. For translational and later-stage preclinical programs, agree on clear milestones and advancement or stop criteria with program leaders and the CTO. For fundamental discovery, combine ongoing scientific dialogue with substantive peer review and five-to-seven-year continuation decisions. Uphold research integrity and reproducibility across all programs.
External Standing
Represent AOI's science to the field, to funders (NIH, ARPA-H, DoD, philanthropy), to scientific advisors, and to academic and industry partners.
Relationship to the Chief Translational Officer
The CSO and CTO are peers who connect discovery with development and clinical investigation. The CSO leads fundamental and exploratory preclinical research; the CTO leads regulated preclinical development, manufacturing, engineering, and trial readiness, and clinical studies. They jointly define the evidence needed to advance a program into development and review the portfolio together. Scientific collaboration continues as programs advance and clinical observations raise new research questions.
First 6 Months
•Develop a scientific strategy with the CEO, CTO, and board, including the proposed research organization, the balance of discovery and translation, initial priorities and resources, and a first set of anticipatory mechanistic programs. Agree on review practices that protect independent discovery and support timely development decisions.
•Begin recruiting priority scientific leaders and independent investigators, with the mix and sequence of appointments shaped by the scientific strategy. Develop the support and affiliation arrangements needed to attract exceptional candidates.
•Establish an agreed plan for laboratory capabilities and launch initial research using in-house resources or external partnerships as appropriate. Work with the CTO and clinical leadership to align research with patient studies and their readiness requirements.
•Co-define the criteria for entering development with the CTO and begin well-funded collaborations with regional academic laboratories. Set the subsequent launch timetable around scientific priorities, recruitment, and facility readiness.
Who We Are Looking For
Essential
•MD/PhD or PhD with a first-rank research record in neuroscience, immunology/neuroinflammation, bioenergetics, or a convergent field.
•Experience building and leading a research organization (institute, department, biotech R&D unit, or focused research organization).
•A track record of attracting outstanding scientists.
•Enthusiasm for a patient-centered research model and for leading a team whose work spans the continuum from discovery to therapy development.
Valued
•Experience supporting independent investigators and collaborative research in academia, research institutes, or industry.
•Scientific credibility in at least one of AOI's initial priority areas.
•Comfort spanning biologics and device/neurotechnology science.
•A demonstrated ability to protect creative discovery while guiding translational programs toward clear milestones.
Practical
AOI welcomes candidates from academia and industry who are excited to build the institute over the coming decade and beyond. The position is full-time in New York City. Candidates should be eager to focus their research leadership on the brain, recovery, and rehabilitation; any continuing research commitments should support that mission. Compensation will be competitive and will include the opportunity to participate in the value created through company formation at AOI.
Leadership Team Engagement
Works closely with the CTO as described above and with clinical leadership to connect research and patient studies. Engages the legal/regulatory team early on regulatory strategy, quality systems, and evidence requirements. Collaborates with the Chief AI Officer on data-rich study design and computational modeling, the COO on laboratory development and recruitment operations, and the CFO on scientific resource planning.
Interested candidates should send their CV and a brief cover note to:
[email protected]
Alex Chamessian retweeted
🚨 NEWS 🚨 A scientist famous for her "magic hands" was unknowingly running a reaction 30 seconds too long & that "mistake" made her results better. This is the tacit knowledge @transfyrai is surfacing in the lab. Out of stealth today with a fantastic piece in the @nytimes 👇
Congrats to @AnnaMarieWagner, @rwegrzyn & the entire Transfyr team!
Many thanks to @carlzimmer at the @nytimes for spending so much time with us and capturing the "magic" of science so beautifully.
"Success can be just as mysterious as failure. Some researchers consistently get experiments to work, earning befuddled admiration from colleagues. Scientists even have a special term for this gift: magic hands.
The idea may come as a surprise to people who don’t spend their lives in labs. Science is not supposed to be magic.
When scientists carry out experiments, they keep careful records, both in lab notebooks and later in published scientific papers. Other researchers use that information to repeat the experiment.
But every scientist discovers sooner or later that essential knowledge is not necessarily written down."
Alex Chamessian retweeted
Thrilled to announce @ginkgo is building 4 new autonomous labs at @MIT, @Caltech, @NorthwesternU, and @UofMaryland! Very jealous of the first crop of grad students who can do all their lab work robotically! More in🧵
Alex Chamessian retweeted
The LLMs are winning Fields medals — usually the domain of formally educated PhD mathematicians who train for years and reason on hard problems with every ounce of brilliance they have.
Yes, training datasets matter. Yes, causal perturbations matter. Yes, depth of phenotyping matters. Yes, there is bias in published literature. Yes to all the critiques :)
But maybe — just maybe — we should suspend our disbelief in the biotech community just a little bit and make sure we are taking the LLM capabilities for a real spin in every way that we possibly can…
The relationship between axonal degeneration and pain in neuropathic conditions is assumed but not often demonstrated. This new study reveals the electrophysiological changes in degenerating axons in the setting of paclitaxel (in rats) biorxiv.org/content/10.64898…
Alex Chamessian retweeted
More grad students/post-docs should start deep tech companies by applying for grants.
1. you are good at writing grants -- a motivated undergrad is not good so you have an advantage vs people running on pure startup hustle.
2. it's non-correlated to what VCs are into at the moment so in case your niche of deep tech isn't in vogue (almost always the case!!) you can still get started building.
3. it's non-dilutive - you'll own more of your company
4. you are used to living on not much money (grad school!) so can get a lot done w/ it.
First $3-5M into @ginkgo when we started out of grad school before we did @ycombinator came from grants. you just make a C-corp, get a bench somewhere, and you can apply! Founders of Ginkgo were co-PI on a DARPA grant with David Baker like a year out of grad school. Even if we'd ended up going into academia it would have been better than doing a post-doc over the first couple of year of ginkgo. Do it!
Congrats @cheyava_falls and @deleon_omics!
I never thought I'd be a Principal Investigator of a federal grant only 1 year out of grad school.
I'm honored to say NSF believes in our mission and is helping us enable low-cost, at-home biochemical testing. Our dream is to make precision health a reality, and to vastly expand human healthspan. But first, we start in precision wellness and build an incredible consumer product that users love.
If you want to learn more, visit deleon.bio and pre-order Otea. If you're interested in collaboration, reach out to me here or via our site.
Alex Chamessian retweeted
Funding for a 4 year phd program that includes time in industry
Today, roughly the same amount of basic research is done in industry as in academia. It’s time our doctoral training reflected that.
@NSF is launching a first-of-its-kind 4-year PhD program at more than 30 universities. Students will spend a year+ embedded with industry partners doing research that informs their dissertation.
Alex Chamessian retweeted
Congrats to our postdoc Hisato Iriki on this 1st author publication in collaboration with Samuele Marro (corresponding author) in @stemcellreports. This was done in direct collaboration with @abbvie!
Induction of human pruriceptors from pluripotent stem cells via transcription factors: Stem Cell Reports cell.com/stem-cell-reports/f…
Alex Chamessian retweeted
Happy 250th Birthday to America!
As the child of Korean immigrants who rebuilt their lives after a devastating war, I am deeply grateful for the extraordinary opportunities this country has provided. Although I was born in Yonkers, New York, I grew up in Alaska—the “Last Frontier.” In many ways, they are opposites, yet both embody something profoundly American: places where people come seeking a better life, where reinvention is possible, and where second chances are real.
As my mother often says, what makes this country unique is that it places far less weight on where you come from or the mistakes you’ve made, and instead gives you the freedom to ask for what you want and pursue it. That level of openness and possibility is rare.
Here’s to another 250 years of opportunity, prosperity, and humanity in a truly remarkable nation.
🤖 Made with AI
Alex Chamessian retweeted
Replying to @JTLonsdale
Thanks for this @JTLonsdale — I’ve been having an exhausting argument with biotech VCs for the last week about not offshoring biotech R&D to cheaper scientific labor in China. Sort of getting nowhere 😛 I don’t know if it’s possible for tech folks to give a warning about the stupidity of Sequoia China, etc, so we don’t have to learn all this the hard way in biotech:
nitter.cf/jrkelly/status/2058368…
Replying to @PeterKolchinsky
The US is 70% of drug profits. Unlike cars, software, or electronics the US is effectively the only market for drugs. That means US govt / FDA can effectively set whatever rules it wants to maintain a strategic industry in the US. If we want to keep Kendall Sq in the US we can, we don’t need to offshore our drug discovery startup industry to China. FDA/USG could block Euro-whatever you are calling it. There’s just not enough of a market ex-US for all of the games you are suggesting Chinese biotechs would play to work. Chinese biotechs would have to bring drugs to market in the US to fund their domestic ecosystem, there’s no escaping it.
It’s just game theory — if US controls the end market, then the US makes the rules to the game.
That’s better for Kendall Sq and better for US patients in the long run. Investors can deal with paying US scientists salaries, it’s not the end of the world.
Easier to keep an industry than to have to try to bring it back later ! We should keep fighting !
Alex Chamessian retweeted
A reasonable average time to funding from idea to getting the money is probably 2-3 years. Executing the work is another 2-3 years if you move quickly. In the age of DeSci + AI, these timelines will literally become geologic in scale. People will develop therapies on an idea while grants are still under resubmission status.




























